West Family Investments Inc. bought a new position in shares of CVS Health Corporation (NYSE:CVS - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 22,696 shares of the pharmacy operator's stock, valued at approximately $176,000.
Other hedge funds have also modified their holdings of the company. Elevation Wealth Partners LLC lifted its holdings in shares of CVS Health by 41.8% in the second quarter. Elevation Wealth Partners LLC now owns 356 shares of the pharmacy operator's stock valued at $37,000 after purchasing an additional 105 shares in the last quarter. Apella Capital LLC grew its holdings in shares of CVS Health by 1.7% during the second quarter. Apella Capital LLC now owns 6,940 shares of the pharmacy operator's stock valued at $724,000 after buying an additional 117 shares in the last quarter. CYBER HORNET ETFs LLC raised its position in CVS Health by 4.1% during the third quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator's stock valued at $259,000 after buying an additional 134 shares during the period. Northwestern Mutual Investment Management Company LLC lifted its stake in CVS Health by 0.3% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator's stock worth $3,219,000 after acquiring an additional 136 shares in the last quarter. Finally, CoreCap Advisors LLC boosted its position in CVS Health by 4.2% during the 2nd quarter. CoreCap Advisors LLC now owns 3,481 shares of the pharmacy operator's stock worth $360,000 after acquiring an additional 139 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.
CVS Health Price Performance
NYSE CVS opened at $93.01 on Friday. CVS Health Corporation has a 1 year low of $69.51 and a 1 year high of $110.68. The company has a fifty day simple moving average of $102.02 and a 200 day simple moving average of $88.86. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The company has a market cap of $118.96 billion, a P/E ratio of 24.61, a P/E/G ratio of 0.85 and a beta of 0.61.
CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The firm had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. During the same quarter last year, the firm posted $1.81 EPS. The company's revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, sell-side analysts predict that CVS Health Corporation will post 8.02 EPS for the current year.
CVS Health Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend was Thursday, July 23rd. CVS Health's dividend payout ratio (DPR) is presently 70.37%.
Analyst Ratings Changes
Several analysts recently commented on CVS shares. Cantor Fitzgerald raised their price target on shares of CVS Health from $100.00 to $110.00 and gave the stock an "overweight" rating in a report on Tuesday, July 7th. Sanford C. Bernstein upped their price objective on shares of CVS Health from $94.00 to $106.00 and gave the company an "outperform" rating in a research note on Tuesday, May 12th. Barclays lifted their target price on shares of CVS Health from $106.00 to $108.00 and gave the company an "overweight" rating in a research note on Thursday, August 6th. UBS Group boosted their price target on shares of CVS Health from $122.00 to $126.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Finally, Morgan Stanley upped their price target on shares of CVS Health from $106.00 to $111.00 and gave the stock an "overweight" rating in a research note on Thursday, June 4th. Twenty-two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $107.17.
Read Our Latest Analysis on CVS
About CVS Health
(
Free Report)
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
Featured Stories
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
